Since early 2024, life sciences organizations have increasingly adopted direct-to-consumer (DTC) models to simplify patient access, reduce costs and address market challenges. While DTC models offer advantages in convenience and market positioning, it also introduces complexities in implementation, compliance and data security.
In this Drug Channels Institute article, Vice President of Business Development, Jordan Armstrong, explores the rise of DTC models, their risks and alternative approaches to best support patient and program needs.
Drug Channels Institute is one of the industry’s leading publications offering expert insights on pharmaceutical economics and the drug distribution systems.